Praxis Precision Medicines, Inc. (PRAX)
| Market Cap | 9.75B +1,146.3% |
| Revenue (ttm) | n/a |
| Net Income | -326.53M |
| EPS | -13.35 |
| Shares Out | 27.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,080 |
| Open | 356.00 |
| Previous Close | 357.13 |
| Day's Range | 346.14 - 356.00 |
| 52-Week Range | 35.21 - 366.52 |
| Beta | 2.78 |
| Analysts | Strong Buy |
| Price Target | 652.18 (+86.42%) |
| Earnings Date | May 7, 2026 |
About PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company’s platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in N... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for PRAX stock is "Strong Buy." The 12-month stock price target is $652.18, which is an increase of 86.42% from the latest price.
News
Praxis Precision assumed with a Buy at Truist
Truist assumed coverage of Praxis Precision (PRAX) with a Buy rating and a price target of $715, up from $700. The company appears well positioned ahead of multiple value-inflecting catalysts…
Praxis Precision Medicines Transcript: Bank of America Global Healthcare Conference 2026
The company is expanding its diversified royalty portfolio through acquisitions and disciplined investments, targeting 20% annual growth and robust cash flow. With a lean team and strong financials, it focuses on high-value, late-stage assets and leverages deep diligence to manage risk and drive compounding returns.
Praxis Precision Medicines Q1 Earnings Call Highlights
Praxis Precision Medicines NASDAQ: PRAX said it is preparing for two potential U.S. product launches while advancing several late-stage clinical programs, as management outlined first-quarter 2026 res...
Praxis Precision price target lowered to $420 from $444 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Praxis Precision (PRAX) to $420 from $444 and keeps a Buy rating on the shares.
Praxis Precision price target raised to $166 from $130 at Wedbush
Wedbush raised the firm’s price target on Praxis Precision (PRAX) to $166 from $130 and keeps an Underperform rating on the shares following quarterly results. The firm continues to hold…
Praxis Precision Medicines Earnings Call Transcript: Q1 2026
Strong Q1 2026 execution with two NDAs accepted, robust clinical progress, and $1.4B cash position. Commercial launches for ulixacaltamide and Relutrigine are on track, with key study readouts expected in 2026.
Praxis Precision Medicines Earnings release: Q1 2026
Praxis Precision Medicines released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Praxis Precision Medicines Quarterly report: Q1 2026
Praxis Precision Medicines has published its Q1 2026 quarterly earnings report on May 7, 2026.
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and ...
Praxis Precision Medicines Slides: Corporate presentation
Praxis Precision Medicines has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, tod...
Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, tod...
Praxis Precision Medicines Proxy statement: Proxy filing
Praxis Precision Medicines filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Praxis Precision Medicines Proxy statement: Proxy filing
Praxis Precision Medicines filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Praxis Precision price target raised to $437 from $412 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Praxis Precision (PRAX) to $437 from $412 and keeps a Buy rating on the shares.
Praxis Precision announces FDA acceptance of ulixacaltamide NDA
Praxis Precision (PRAX) announced that the FDA has accepted for review its new drug application, or NDA, for ulixacaltamide HCl for the treatment of essential tremor in adults. The FDA…
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully int...
Praxis Precision initiated with a Strong Buy at Raymond James
Raymond James last night initiated coverage of Praxis Precision (PRAX) with a Strong Buy rating and $815 price target The firm says the bear thesis on the name “is a…
Praxis Precision initiated with a Strong Buy at Raymond James
Raymond James initiated coverage of Praxis Precision (PRAX) with a Strong Buy rating and $815 price target
Praxis Precision announces topline results from EMBRAVE Part A trial
Praxis Precision (PRAX) announced topline results from the EMBRAVE Part A trial of elsunersen in pediatric patients with early-seizure onset SCN2A developmental and epileptic encephalopathy. Elsunerse...
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observe...
Praxis Precision announces FDA acceptance for priority review of relutrigine NDA
Praxis Precision (PRAX) announced that the FDA has accepted for priority review its new drug application for relutrigine, for the treatment of SCN2A and SCN8A developmental and epileptic encephalopath...
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
FDA assigned PDUFA target action date of September 27, 2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous sys...
Praxis Precision Medicines Transcript: TD Cowen 46th Annual Health Care Conference
NDA filings for Ulyxa and relumitragene are advancing, with Ulyxa under standard review to optimize economic and regulatory outcomes. Launch preparations include robust disease awareness, specialty pharmacy distribution, and a large sales force, while pipeline programs like vormetragine and elsunersen are progressing toward key data readouts and filings.
Praxis Precision initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of Praxis Precision (PRAX) with an Outperform rating and $500 price target The firm launched coverage of the neuroscience biotech sector with a “portfolio of high…